Table 2.

Greater improvements in graft survival after KT for black compared with white adults in the United States

Transplant YearWhite RecipientsBlack Recipients
1-Year aHR (95% CI)3-Year aHR (95% CI)5-Year aHR (95% CI)1-Year aHR (95% CI)3-Year aHR (95% CI)5-Year aHR (95% CI)
LDKTa
 1990–1992ReferenceReferenceReferenceReferenceReferenceReference
 1993–19941.03 (0.85 to 1.24)1.12 (0.96 to 1.31)1.05 (0.92 to 1.19)0.82 (0.59 to 1.14)0.92 (0.73 to 1.17)0.94 (0.78 to 1.15)
 1995–19961.12 (0.87 to 1.44)1.19 (0.98 to 1.45)1.09 (0.93 to 1.28)0.87 (0.60 to 1.25)1.01 (0.78 to 1.32)0.92 (0.74 to 1.14)
 1997–19980.94 (0.73 to 1.22)1.08 (0.89 to 1.32)1.05 (0.90 to 1.23)0.59 (0.40 to 0.86)0.71 (0.54 to 0.92)0.72 (0.58 to 0.89)
 1999–20000.84 (0.65 to 1.08)1.10 (0.90 to 1.34)1.01 (0.86 to 1.19)0.66 (0.46 to 0.94)0.78 (0.60 to 1.02)0.75 (0.61 to 0.93)
 2001–20020.78 (0.61 to 1.01)1.05 (0.85 to 1.29)0.98 (0.83 to 1.16)0.56 (0.39 to 0.80)0.79 (0.61 to 1.02)0.78 (0.63 to 0.96)
 2003–20040.70 (0.54 to 0.89)0.97 (0.79 to 1.20)0.89 (0.75 to 1.05)0.47 (0.33 to 0.66)0.69 (0.53 to 0.89)0.67 (0.54 to 0.83)
 2005–20060.63 (0.49 to 0.81)0.85 (0.69 to 1.04)0.80 (0.68 to 0.95)0.40 (0.28 to 0.57)0.58 (0.44 to 0.76)0.57 (0.46 to 0.71)
 2007–20080.46 (0.35 to 0.59)0.69 (0.56 to 0.85)0.67 (0.56 to 0.79)0.39 (0.27 to 0.57)0.61 (0.46 to 0.80)0.60 (0.48 to 0.75)
 2009–20100.44 (0.34 to 0.57)0.64 (0.52 to 0.79)0.30 (0.20 to 0.44)0.47 (0.35 to 0.62)
 2011–20120.40 (0.30 to 0.52)0.30 (0.20 to 0.45)
DDKTb
 1990–1992ReferenceReferenceReferenceReferenceReferenceReference
 1993–19941.02 (0.94 to 1.11)1.02 (0.95 to 1.09)1.02 (0.97 to 1.08)0.90 (0.81 to 1.02)0.92 (0.85 to 1.01)0.90 (0.84 to 0.97)
 1995–19960.79 (0.70 to 0.89)0.85 (0.77 to 0.93)0.87 (0.81 to 0.95)0.70 (0.61 to 0.81)0.74 (0.67 to 0.83)0.75 (0.69 to 0.82)
 1997–19980.66 (0.58 to 0.74)0.78 (0.70 to 0.86)0.80 (0.74 to 0.87)0.57 (0.49 to 0.67)0.64 (0.58 to 0.72)0.67 (0.61 to 0.74)
 1999–20000.66 (0.58 to 0.76)0.78 (0.70 to 0.86)0.81 (0.74 to 0.88)0.62 (0.53 to 0.71)0.69 (0.62 to 0.77)0.69 (0.63 to 0.76)
 2001–20020.58 (0.51 to 0.66)0.74 (0.67 to 0.82)0.77 (0.71 to 0.84)0.52 (0.45 to 0.61)0.59 (0.53 to 0.66)0.60 (0.55 to 0.66)
 2003–20040.48 (0.42 to 0.55)0.64 (0.57 to 0.70)0.67 (0.61 to 0.73)0.48 (0.41 to 0.55)0.57 (0.51 to 0.64)0.55 (0.50 to 0.61)
 2005–20060.45 (0.39 to 0.51)0.58 (0.52 to 0.64)0.60 (0.55 to 0.66)0.41 (0.36 to 0.48)0.48 (0.43 to 0.54)0.48 (0.43 to 0.52)
 2007–20080.35 (0.31 to 0.40)0.46 (0.42 to 0.52)0.52 (0.47 to 0.56)0.37 (0.32 to 0.42)0.41 (0.37 to 0.45)0.41 (0.37 to 0.45)
 2009–20100.36 (0.31 to 0.41)0.47 (0.43 to 0.52)0.29 (0.25 to 0.33)0.36 (0.32 to 0.40)
 2011–20120.28 (0.24 to 0.32)0.24 (0.20 to 0.28)
  • Table shows the 1-year, 3-year, and 5-year aHRs comparing all-cause graft loss in recent transplant cohorts to the earliest transplant cohort (1990–1992). When comparing black and white recipients, there were greater improvements in graft survival over time for black recipients. —, data not available; DSA, donor service area; PRA/CPRA, panel reactive antibody/calculated panel reactive antibody.

  • a LDKT models adjusted for donor age, donor race/ethnicity, donor relationship, donor/recipient weight ratio, HLA mismatches, peak plasma renin activity (PRA)/CPRA, previous solid organ transplant, recipient age at transplant, recipient body mass index, recipient cause of ESRD, recipient hepatitis C serology, recipient insurance coverage, recipient race/ethnicity, recipient sex, and time on RRT.

  • b DDKT models adjusted for cold ischemia time, donation after circulatory death, donor age, donor cause of death, donor history of diabetes, donor history of hypertension, pumped donor kidney, donor race/ethnicity, donor serum creatinine, donor/recipient weight ratio, HLA mismatches, organ shipped outside recovery DSA, peak PRA/CPRA, previous solid organ transplant, recipient age at transplant, recipient body mass index, recipient cause of ESRD, recipient hepatitis C serology, recipient insurance coverage, recipient race/ethnicity, recipient sex, and time on RRT.